AGREF yields 2500.00% · PFE yields 6.20%● Live data
📍 AGREF pulled ahead of the other in Year 1
Combined, AGREF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AGREF + PFE for your $10,000?
Argonaut Resources NL operates as a mineral exploration and development company in Zambia and Australia. It primarily explores for iron oxide, lithium, uranium, copper, gold, cobalt, and nickel deposits. The company holds 90% interests in the Lumwana West project comprising one exploration licence; the Kamapanda project consisting of one exploration licence and covering an area of 225 square kilometers; and the Kalaba East project located in North-Western province, Zambia. It also has 80% interest in the Higginsville joint venture project covering one exploration licence located in the Eastern Goldfields of Western Australia; and holds 100% interest in the Murdie project comprising two exploration licence covering an area of 1,105 square kilometers located in Eastern Gawler Craton of South Australia. In addition, the company holds interest in the Torrens joint venture project covering one exploration licence; and the Frome project comprising three exploration licence covering an area of 2,894 square kilometers located in South Australia. Further, it holds 100% interest in the Kroombit project consisting of ML 5631 and the surrounding mineral development licence MDL 2002 located in Queensland; and the Aroona project comprising one exploration licence located in Southern Willouran Ranges, South Australia. The company was formerly known as Star Mining Corporation NL. Argonaut Resources NL was incorporated in 1985 and is based in Adelaide, Australia.
Full AGREF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.